PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study

Giulia Bertolini, Luca Bergamaschi, Andrea Ferrari, Salvatore L. Renne, Paola Collini, Cecilia Gardelli, Marta Barisella, Giovanni Centonze, Stefano Chiaravalli, Cinzia Paolino, Massimo Milione, Maura Massimino, Michela Casanova and Patrizia Gasparini

Abstract

Background: Rhabdomyosarcomas (RMSs) are the most frequent soft tissue sarcoma in children and adolescents, defined by skeletal muscle differentiation and the status of FOXO1 fusions. In pediatric malignancies, in particular RMS, scant and controversial observations are reported about PD-L1 expression as a putative biomarker and few immune checkpoint clinical trials are conducted.

Methods: PD-L1 assessment was evaluated by immunohistochemistry (IHC) utilizing two anti-PDL1 antibodies, in a pilot cohort of 25 RMS. Results were confirmed in primary and commercial RMS cell lines by cytofluorimetric analysis and IHC.

Results: PD-L1 expression was detectable, by both anti-PD-L1 antibodies, in the immune contexture of immune cells infiltrating and/or surrounding the tumor, in 15/25 (60%) RMS, while absent expression was observed in neoplastic cells. Flow cytometry analysis and PD-L1 IHC of commercial and primary RMS cell lines confirmed a very small percentage of PD-L1 positive-tumor cells, under the detection limits of conventional IHC. Interestingly, increased PD-L1 expression was observed in the immune contexture of 4 RMS cases post chemotherapy compared to their matched pre-treatment samples.

Conclusion: Here we identify a peculiar pattern of PD-L1 expression in our RMS series with scanty positive-tumor cells detected by flow cytometry, and recurrent expression in the immune cells surrounding or infiltrating the tumor burden.

Keywords: Pediatric malignancies, Rhabdomyosarcoma, Soft tissue sarcoma, PD-L1 expression, Flow cytometry, Immunohistochemistry, Primary cell lines
PD-1, a type I transmembrane glycoprotein cell surface receptor expressed on T- and pro-B cells, is an immunoreceptor belonging to the CD28/CTLA-4 family of T-cell regulators and, functioning as an immune check-point, plays a critical role in downregulating the immune system by preventing the activation of T-cells. PD-1 point, plays a critical role in downregulating the immune T-cell regulators and, functioning as an immune checkpoint receptor expressed on T- and pro-B cells, is an immune checkpoint inhibitor. The PD-1/PD-L1 immune checkpoint pathway has proved to improve adults patients’ survival, but with less toxicity than conventional treatments, possibly stimulating the anti-tumor immunity by activating the patients’ own immune system [7].

Encouraging clinical benefits of PD-1/PD-L1 checkpoint blockade have been demonstrated in over 15 different malignancies, among which melanoma [8–10], lung cancer [11, 12], genitourinary tract cancer [13], Hodgkin lymphoma [13] and sarcoma [14] confirming that host immune responses are essential in most neoplasms [15]. As the PD-1 pathway may be a key mechanism of immune escape in a subgroup of patients in several malignancies, PD-L1 expression in tumor or inflammatory cells is a candidate biomarker [12]. However, the only limitation is that PD-L1 status is not effective in identifying the fraction of PD-L1 negative patients that may also benefit from immune therapy [7, 16].

For pediatric malignancies, only a few anti-PD-1 and anti-PD-L1 clinical trials are ongoing and little is known regarding the prognostic and predictive implications of PD-L1 in childhood tumors, in particular RMS. Moreover, to our knowledge, no responses have been reported to anti-PD1 or anti-PD-L1 as a single drug in RMS. Thereby, in an attempt to further describe the immune environment of RMS, we evaluated PD-L1 expression, in a cohort of 25 RMS specimens utilizing two anti-PD-L1 antibodies by immunohistochemistry (IHC) approach on Formalin-Fixed Paraffin Embedded (FFPE) RMS tissues and cytoblocks from RMS cell lines. Our observations were further confirmed by flow cytometry analysis in RMS cell lines, both commercial and primary cultures derived from surgical RMS specimens.

**Methods**

**Patients and tissue samples**

This study was conducted on a retrospective cohort of patients who were pathologically diagnosed with RMS at Fondazione IRCCS Istituto Nazionale dei Tumori, Milano. Twenty-five FFPE RMS tissues were retrieved from the archives of the Department of Diagnostic Pathology and Laboratory Medicine of our Institute and were available for evaluation of PD-L1 expression by IHC analysis.

The clinical pathologic variables such as sex, age, tumor size, histology, IRS, site of onset, stage, and follow up information were assessed and reviewed. The study was approved by the Internal Review Board and the Ethics Committee of the institutions (CE N. INT 133–16). All patients’ parents or their guardians gave their written informed consent for diagnosis and research activities when they were admitted to the hospital. All cases were assessed for the presence of PAX3/7-FOXO1 fusion transcript. In all cases FFPE material was available for reclassification, following the updated WHO criteria for soft tissue sarcomas (2013) into ERMS and ARMS by expert pediatric sarcoma pathologists (SLR, PC, MB).

**Immunohistochemistry**

PD-L1 protein expression, together with several antibodies specific for the immune infiltrate component, was investigated by IHC methods on consecutive slides from FFPE RMS tumor samples. Specifically for PD-L1 two different antibodies were considered: clone anti-PD-L1-CD274, SP142 (Roche Diagnostic, USA), and clone anti-PD-L1 22C3 (Dako, Glostrup, Denmark). Briefly, 2.5/3 μm-thick were cut from paraffin blocks, dried, de-waxed, rehydrated; in particular slides were unmasked with Dako PT-link, EnVision™ FLEX Target Retrieval Solution (Dako, Glostrup, Denmark) High pH, 96 °C - 30 min for PD-L1-CD274, (SP142, dilution 1:100), and Low pH, 98 °C – 30 min for PD-L1 clone 22C3 (Dako, Denmark, dilution 1:50). Finally, both antibody were incubated with a commercially available detection kit (EnVision™ FLEX+, Dako, Denmark) in an automated Immunostainer (Dako Autostainer System). A FFPE H460 cell line xenograft was utilized as a positive control for PD-L1 marked expression within tumor cells.

In addition to PD-L1, the following antibodies were utilized to characterize the immune infiltrate component: CD3 (anti-T cells, Dako), CD68 (anti-macrophage and monocyte, Dako), CD20 (anti-B cells, Dako), CD163 (anti-macrophage, Novocastra), CD56 (anti-T and natural killer cells, Dako), and CD57 (anti-T and natural killer cells, Dako). Antibodies were utilized with the following dilution: PD-L1 (1:100), CD3 (1:100), CD20 (1:400), CD68 (1:3000), CD163 (1:200), CD57 (1:100), CD56 (1:400).

**Interpretation of PD-L1 expression by immunohistochemistry**

For both antibodies, PD-L1 staining was evaluated in tumor cells (TC) and in non-neoplastic cells enclosed in stromal microenvironment, named tumor infiltrating cells (IC) by two experienced pathologists (SLR, PC, MB). According to PD-L1 antibodies manufacturer’s we
distinguished different classes of staining and assigned scores following the summarized table:

| TC score | TC definition | IC score | IC definition |
|----------|---------------|----------|---------------|
| TC 0     | <1%           | IC 0     | <1%           |
| TC 1     | 1%≥5%         | IC 1     | 1%≥5%         |
| TC 2     | 5%≥50%        | IC 2     | 5%<10%        |
| TC 3     | ≥50%          | IC 3     | ≥10%          |

Cell lines
A panel of cell lines was analyzed by flow cytometry analysis to verify the presence of PD-L1 protein expression in an in vitro model composed of merely tumor RMS cells. RH30 (ARMS) and NCI-H460 (large cell lung cancer) cell lines were obtained from the American Type Culture Collection (ATCC) and grown according to guidelines. On the other hand, five primary RMS cell cultures were established from fresh tumor specimens by mechanical and collagenase II enzymatic dissociation, followed by culturing and propagating in Amniomax-C100 medium (Invitrogen), and characterized for the PAX3/7-FOXO1 translocation by FISH. For each cell line, cell blocks were also prepared and utilized for IHC analysis of PD-L1.

Flow cytometry analysis
For cell staining, single cell suspensions of all 7 cell lines were washed and incubated in staining buffer (PBS 1× containing 1% BSA and 2 mM EDTA) with anti-PDL-1 (clone B7-H1, E-bioscience) and appropriate IgG Isotype control, all diluted 1:10 for 30 min at 4 °C cells. Prior to acquisition, samples were incubated with 7-AAD viability staining solution (10 μl/tube) for exclusion of dead cells. Flow cytometry data were acquired using FACS Calibur cytometer (Becton Dickinson) and analyzed by Flowjo software.

Results
Clinicopathological features
The retrospective cohort comprised 25 RMS (13 ERMS, 11 ARMS, and 1 RMS with sclerosing features) tissues. Our series included ERMS and ARMS (fusion transcript positive and negative) either collected at diagnosis (pre-treated and not), at time of progression of disease, or during therapy, so to recapitulate different disease courses of RMS malignancy. Clinical and pathological characteristics are summarized in.

PD-L1 protein status and characterization of immune contexture by IHC
To evaluate PD-L1 protein expression in RMS and characterize the immune cells present within each specimen, we performed a thorough IHC analysis in our cohort of 25 RMS histological samples. Two different anti PD-L1 antibodies were utilized and for both PD-L1 staining was evaluated and scored in tumor cells (TC) and in non-neoplastic cells enclosed in stromal microenvironment, named tumor infiltrating cells (IC) for each RMS specimen (Table 1).

IHC results were comparable for both PD-L1 antibodies, though immunostaining with clone 22C3 proved to be a bit more fainter. Overall, PD-L1 expression for both antibodies resulted completely absent in tumor cells (TC0) of our entire cohort. Interestingly, PD-L1 expression was observed in the immune contexture (IC1-IC3) in 15/25 (60%; 6/11 ARMS, 9/14 ERMS) RMS evaluated. Of the 15 RMS displaying PDL1 expression 5 RMS scored IC3, 8 RMS had IC2 and only one RMS showing occasional PD-L1 expression in single immune cells outside the tumor burden (IC1). We were also able to describe a peculiar staining pattern for the PDL1-expressed RMS: a marked and continuous protein expression in both the immune cells infiltrating and surrounding the tumor burden. At last, PD-L1 expression was absent both in the tumor cells (TC0) and in the immune component (IC0) in 10/25 (40%) RMS specimens (Fig. 1a and b). As opposed to our positive control (H460) that clearly expressed PD-L1 in tumor cells, none of our 25 RMS series revealed expression in tumor cells (Fig. 1g and h).

Moreover, to better define PD-L1 protein expression in the immune component (infiltrating or surrounding the tumor), a panel of lineage specific antibodies (CD3, CD68, CD20, CD163 CD56, CD57) was utilized, on samples with available material (Additional file 1: Table S2). Our observations revealed that PD-L1 staining co-localized with area showing marked positivity for CD3+ T-lymphocytes and CD68+ macrophages, while lack of co-localization with tumor cells is highlighted by nuclear staining of myogenin in RMS tissue (Fig. 2a-e).

Although no statistical analysis was possible due to the limited size and the heterogeneity of the cohort, it can be observed that PD-L1 staining in the IC does not seem to correlate with neither the fusion transcripts status, the outcome nor any other clinical feature.

PD-L1 expression by flow cytometry in cell lines
In order to confirm absence of PD-L1 staining by IHC in the neoplastic cells, we evaluated the protein expression by flow cytometry in cancer cell lines. A total of 6 RMS cell lines were available for FACS analysis: two commercial cell line (RH30 and RD) and 5 primary cell
| ID  | Histotype | Fusion Transcript | PD-L1 IHC | Comments | Status | T    | N    | M    | IRS | Outcome |
|-----|-----------|------------------|-----------|----------|--------|------|------|------|------|---------|
| RMS1| ERMS      | negative         | 0 0 2 2   | IC only outside tumor | In therapy | T2B  | N0   | M1   | 4    | DOD     |
| RMS2| ARMS      | PAX7-FOXO1       | 0 0 0 0   |          | Pre-treated | T1   | N0   | M0   | 1    | DOD     |
| RMS3| ERMS      | negative         | 0 0 0 0   |          | In therapy | T2B  | N0   | M1   | 4    | DOD     |
| RMS4| ARMS      | negative         | 0 0 0 0   |          | At diagnosis | T2B  | N0   | M1   | 4    | DOD     |
| RMS5| ERMS      | negative         | 0 0 0 0   |          | At diagnosis | T2A  | N0   | M1   | 4    | 1°RC    |
| RMS6| ARMS      | negative         | 0 0 3 3   | Few cells in IC outside and infiltrating tumor | At diagnosis | T2A  | N1   | M1   | 4    | DOD     |
| RMS7| ARMS      | PAX3-FOXO1       | 0 0 1 1   | Few cells in IC outside and infiltrating tumor | At diagnosis | T1A  | N0   | M1   | 4    | DOD     |
| RMS8| ERMS      | negative         | 0 0 2 2   | IC only outside tumor | Pre-treated | T2B  | N0   | M0   | 3    | 1°RC    |
| RMS9| ERMS      | negative         | 0 0 3 3   | IC only outside tumor | At diagnosis | T2B  | N0   | M0   | 3    | 1°RC    |
| RMS10| ARMS     | negative         | 0 0 2 2   | IC only outside tumor | Pre-treated | T2B  | N0   | M0   | 3    | 2°RC    |
| RMS11| RMS      | negative         | 0 0 0 0   |          | At diagnosis | T2B  | N1   | M0   | 3    | DOD     |
| RMS12| ARMS     | PAX7-FOXO1       | 0 0 2 2   | IC only outside tumor | At diagnosis | T2B  | N1   | M0   | 3    | 1°RC    |
| RMS13| ARMS     | PAX7-FOXO1       | 0 0 3 3   | IC outside and infiltrating tumor | Pre-treated | T2A  | N0   | M1   | 3    | DOD     |
| RMS14| ARMS     | PAX3-FOXO1       | 0 0 0 0   |          | At diagnosis | T1A  | N0   | M1   | 4    | DOD     |
| RMS15| ARMS     | negative         | 0 0 2 2   | IC only infiltrating tumor | At diagnosis | T1A  | N0   | M0   | 3    | 1°RC    |
| RMS16| ARMS     | PAX3-FOXO1       | 0 0 3 3   | IC outside and infiltrating tumor | At diagnosis | T2B  | N1   | M0   | 3    | 1°RC    |
| RMS17| ARMS     | PAX3-FOXO1       | 0 0 0 0   |          | At diagnosis | T2B  | N1   | M1   | 4    | DOD     |
| RMS18| ERMS     | negative         | 0 0 0 0   |          | At diagnosis | T2B  | N0   | M0   | 3    | 1°RC    |
| RMS19| ERMS     | negative         | 0 0 2 2   | IC outside and infiltrating tumor | post-treatment | T2B  | N0   | M0   | 3    | 1°RC    |
| RMS20| ARMS     | negative         | 0 0 0 0   |          | post-treated | T1A  | N0   | M0   | 3    | 1°RC    |
| RMS21| ARMS     | negative         | 0 0 2 2   | IC outside and infiltrating tumor | post-treatment | T2B  | N1   | M0   | 3    | DOD     |
| RMS22| ARMS     | negative         | 0 0 2 2   | IC outside and infiltrating tumor | At diagnosis | T2B  | N0   | M0   | 3    | 1°RC    |
| RMS23| ARMS     | negative         | 0 0 3 3   | IC outside and infiltrating tumor | post-treatment | T2B  | N0   | M0   | 3    | 1°RC    |
| RMS24| ARMS     | negative         | 0 0 0 0   |          | At diagnosis | T2B  | N0   | M0   | 3    | 1°RC    |
| RMS25| ERMS     | negative         | 0 0 2 2   | IC outside and infiltrating tumor | post-treatment | T2B  | N0   | M0   | 3    | 1°RC    |
cultures established from surgical tumor specimens whose corresponding histological samples were also analyzed by IHC (RMS12-RMS16). All results are summarized in Table 2.

Utilizing a lung cancer cell line H460 as a positive control for PD-L1 positivity (97% positive for PD-L1), all RMS cell lines exhibited a relatively low expression ranging from 2 to 12% (average of PD-L1 positive cells; Fig. 3a).

Cytoblocks derived from RMS cell lines were prepared and assessed for expression of PD-L1 in tumor cells by IHC to verify the correlation between results obtained by flow cytometry and IHC methodologies. Indeed, PD-L1 staining was observed in very few tumor cells (1–8 cells/slide) of RH30 and primary cell line RMS-B1 (Fig. 3b).

**Dynamic changes of PD-L1 expression induced by chemotherapy**

Among our cohort, 8 RMS tissues from 4 RMS patients were evaluated at different tumor progression time. Specifically, RMS2 and RMS13 (ARMS) represented the first progression of disease and its corresponding relapse sample. Moreover, RMS18, RMS22 and RMS24 were all ERMS tissues obtained at diagnosis, while RMS19, RMS23 and RMS25 were their corresponding tumor progression post several lines of treatment (possible cycle treatments: Vincristine and Irinotecan, Vinorelbine and Endoxan, Ifosfamide/Doxorubicina/Actinomicina and Ciclofosfamide/ Doxorubicina/ Vincristina). Interestingly, PD-L1 expression was reported as negative in RMS2 (Fig. 4), RMS24, RMS18 (Additional file 2: Figure S1A and C) or a weakly expressed in RMS22 (Additional file 2: Figure S1E) in samples collected at diagnosis and first tumor progression, but it revealed to show a marked PD-L1 staining in the immune component both surrounding and infiltrating the tumor burden in the corresponding tissue obtained post therapy (Fig. 4 and Additional file 2: Figure S1B,D,F). Our results strongly suggest that damages and selective pressure caused by chemotherapy can reactivate a tumor immune response.

**Discussion**

Successful results obtained with pembrolizumab and nivolumab in melanoma, NSCLC, sarcoma and other malignancies [10–12, 17, 18], have been recently reported, bringing forward immune checkpoint inhibitors as potential treatment options. Since there has been limited research to investigate the clinical and prognostic significance of the PD-1/PD-L1 axis in pediatric malignancies, in the present study we assess the presence of PD-L1 expression in pediatric RMS primary tumors and corresponding cell lines. Our results identify PD-L1 expression in 60% of RMS analyzed, detecting mild/moderate staining uniquely in the immune cells surrounding the tumor burden and/or in those infiltrating the tumor, thus never observing expression in the neoplastic cells.

Current studies have pointed out that high expression of PD-L1 in tumor cells is associated with poor prognosis in NSCLC [11, 12, 19], ovarian cancer [20] and kidney cancer [21], melanoma [22], renal cancer [21], Hodgkin lymphoma [16] and bone and soft tissue sarcoma [15, 23, 24]. Our study demonstrated, by using two different anti-PD-L1 clones that PD-L1 expression is confined in immune cells infiltrating and/or surrounding the tumor burden, but not in RMS tumor cells. To further confirm our results, we
assessed PD-L1 expression of RMS cell lines by two different techniques (flow cytometry and IHC on cytoblocks) and using two different clones of anti-PD-L1 antibodies: we were able to detect a very low percentage of tumor cells by flow cytometry, due to the high sensitivity of this technique, that accordingly was hardly detectable with a conventional IHC approach on FFPE cytoblocks. This data confirms the almost completely absence of PD-L1 expression in RMS tumor cells, even when different techniques and antibody clones were utilized. Low expression of PD-L1 in RMS was also reported by Torabi et al. detecting positivity in 3/96 cases in a TMA [24]. Our data are in contrast with those reported by Kim et al. showing an expression of PD-L1 in tumor cells in 37% (12/32) of specimens [15]. However, discordant observations in expression of PD-L1 could be explained by use of different anti-PD-L1 antibodies, staining procedures, and antigen retrieval techniques.

Interestingly, an important subdivision of anticancer immunity in humans into three main phenotypes is represented by Chen & Mellman: immune-desert, immune-excluded and immune-inflamed. Accordingly to this classification, our observations enabled us to subdivide our cohort in 4 ‘immune-inflamed’ RMS, displaying expression of PDL1 in immune cells surrounding and within the tumor burden, which may likely respond to anti-PD-L1/PD-1 therapy, and 5 ‘immune-excluded’ RMS with PD-L1 staining present in immune cells that do not penetrate the parenchyma of the tumor but rather are retained in the surrounding stroma, which are expected to rarely respond to PD-L1/PD-1 agents [25]. At last, 7 specimen were revealed to be ‘immune-desert’ and characterized by very few T-cells in either the parenchyma or the stroma of the tumor burden, therefore not responsive to PD-L1/PD-1 agents [25].

Dynamic changes of PD-L1 protein expression were observed in 4 RMS tumors evaluated at diagnoses/first progression of disease and at a (second) tumor progression post-treatment, suggesting that damages

---

**Table 2** PD-L1 expression in FFPE RMS tissues, derived cell lines and cytoblocks

| ID # | Cell line | Fusion Transcript | PD-L1 (IHC) FFPE tissue | Flow Cytometry DERIVED CELL LINE | PD-L1 (IHC) CYTOBLOCK (cell line) |
|------|-----------|------------------|------------------------|---------------------------------|----------------------------------|
| RMS12| RMS-GD    | PAX7-FOXO1       | 0                      | 2,10%                           | 0                                |
| RMS13| RMS-ME    | PAX7-FOXO1       | 0                      | 1,93%                           | 0                                |
| RMS14| RMS-GJ    | PAX3-FOXO1       | 0                      | 5,55%                           | 0                                |
| RMS15| RMS-SG    | negative         | 0                      | 2,83%                           | 0                                |
| RMS16| RMS-BI    | PAX3-FOXO1       | 0                      | 12,25%                          | 1–5 TC                           |

---

**Fig. 2** Characterization of infiltrating immune contexture. (a) RMS10 with a PD-L1 scoring of TC0 and IC2 in the areas surrounding the tumor with a faint staining and in a focal pattern (as pointed out by the arrows). (b-e) Magnification (40X) of the area within the box, displaying different IHC expression staining: (b) PD-L1(Clone 15F124) expression in the immune contexture and not in tumor cells, (c) Myogenin positive expression of neoplastic cells, (d) CD3 revealing T-lymphocytes positivity, (e) and CD68 staining confirming macrophages positivity.
induced by chemotherapy treatments in tumor cells and stroma may foster an inflammatory microenvironment and recruitment of PD-L1 expressing immune cells, creating an immune contexture possibly druggable by immune checkpoint inhibitors. Indeed randomized clinical trials using immunotherapy in second line after chemotherapeutic treatments in NSCLC indicated successful response rate [12, 26]. These results also reinforce the concept to perform biopsies, when possible, prior of initiating an immune checkpoint treatment to confirm the immune contexture status at that particular time, as it is easily influenced and prone to changes [even if the biomarker validity of PD-L1 positivity is highly debatable].

In view of our results, the lack of expression by the neoplastic cells discourages us to consider RMS an immunogenic tumor possibly explaining the lack of literature of immune checkpoint inhibitors in pediatric RMS. However, the distinct PD-L1 expression pattern observed in our cohort, could be critical in discriminating ‘immune-inflamed’ from ‘immune-excluded’ specimen, making a significant difference in discriminating those patients that may benefit from PD-1/PD-L1 therapy.
Conclusion
To the date, clinical trials with immune checkpoint inhibitors in pediatric malignancies are few and with mainly unsatisfactory results, thus an effort to characterize the immune contexture is needed. In this study, we demonstrate by different techniques and in multiples setting the low expression of PD-L1 by RMS, and we observed a possible complementary role of chemotherapy as igniter of ‘inflamed’ tumors. Taken altogether these data may suggest the possibility of a combination with conventional chemotherapy and PD-L1 checkpoint blockade.

Additional files

Additional file 1: Table S1. Clinico-pathological features. A summary of all the clinic-pathological features of the analyzed cohort. Table S2. Characterization of the immune infiltrate contexture. This table display the results of the IHC performed, only on RMS with abundant FFPE material, to characterized the immune contexture of RMS. (ODP 30 kb)

Additional file 2: Figure S1 PD-L1 expression pre and post therapy. Changes in PD-L1 expression are revealed in pre- and post-treatment RMS tissue from the same patients: RMS24, RMS18, RMS22 (A,C and E), all at diagnosis and with no prior treatment, show absence or a mild expression of PD-L1 in the immune component; RMS25, RMS19, RMS23 (B,D and F), all following several lines of treatments, mainly chemotherapy, display a moderate expression in the immune contexture outside and infiltrating the tumor burden. (PPTX 6110 kb)

Abbreviations
ARMs: Alveolar RMS; ERMS: Embryonal RMS; FFPE: Formalin-Fixed Paraffin Embedded; FISH: Fluorescent in situ hybridization; IC: Infiltrating cells; IHC: Immunohistochemistry; NSCLC: Non-small cell lung cancer; RMS: Rhabdomyosarcoma; TC: Tumor cells

Acknowledgements
Special thanks goes to Dr. Gabriella Sozzi for her valuable supervision.

Funding
This project was supported by Associazione Bianca Garavaglia: (ABG. A/15/01 N of GS, A/15/01H of PC and ABG A/15/01 L of RL), and AIRC (Associazione Italiana per la Ricerca sul Cancro) 12162 Special Program “Innovative Tools for Cancer Risk Assessment and Early Diagnosis”, S × 1000 of GS, and IG13403 of LR, and Fellowship Umberto Veronesi of GB. The funding body did not have any role in the study design, nor the data collection, analysis and interpretation as well as writing of the manuscript.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
CM and GP jointly conceived and designed the study. BL, BG, FA, CP, GC, SRL, MB, CS, MM, GP all took part in the development of the methodology. BL, BG, FA, CP, PC, PS, CM, SLR and GP participated in the acquisition, analysis and interpretation of data (IHC analysis, acquisition of images). Interpretation of IHC was performed by PC, SLR, MM, MB. Writing, review, and/or revision of the manuscript was carried out by BL, BG, FA, CP, SLR, MM, CM and GP. Images and tables were carefully prepared by GP, CP, SLR, BM, BL, BG, FA, PC, CG, CS, MWA, CM and GP supervised administrative, technical, or material support. The overall project was supervised by MWA, FA, CM and GP. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This retrospective study was approved by the Internal Review Board and the Ethics Committee of the our Institutions with the following protocol number: CE N. INT 133–16. All patients’ parents or their guardians gave their written informed consent for diagnosis and research activities upon admission to the hospital.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 Department of Research, Tumor Genomics Unit, Genomics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, via venezian 1, 20133 Milan, Italy.
2 Department of Pediatric Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
3 Soft tissues and bone, and pediatric pathology unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
4 Pathology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
5 Unit of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
6 Clinical Research Lab (CRAB), Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Received: 24 November 2017 Accepted: 25 May 2018

References
1. Sultan I, Ferrari A. Selecting multimodal therapy for rhabdomyosarcoma. Expert Rev Anticancer Ther. 2010;10:1285–301.
2. Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, Parham DM, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma—a report from the intergroup rhabdomyosarcoma study IV. J Clin Oncol. 2003;21:78–84.
3. Meggiorni F, Ciaffi S, McDowell HP, Felsani A, Carrero S, Guffanti A, et al. Deep sequencing the microRNA profile in rhabdomyosarcoma reveals down-regulation of miR-378 family members. BMC Cancer. 2014;14:880.
4. Chen X, Stewart E, Shetat AA, Qu C, Bahrami A, Hatley M, et al. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell. 2013;24:710–14.
5. Newton WA Jr, Soule EH, Hamoudi HM, Shimada H, Belfangady M, et al. Histopathology of childhood sarcomas, intergroup rhabdomyosarcoma studies I and II: clinicopathologic correlation. J Clin Oncol. 1988;6:57–75.
6. Nalempati S, Hawkins DS. Rhabdomyosarcoma: review of the Children’s oncology group (COG) soft-tissue sarcoma committee experience and rationale for current COG studies. Pediatr Blood Cancer. 2012;59:510–9.
7. van Dam LS, de Z, V, Meyer-Wentrup FA: The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer. Expert Rev Anticancer Ther. 2015;15:190–197.
8. Wolchok JD, Hodi FS, Hwu WJ, Kefford R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–28.
9. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Keefe R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134–44.
10. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2016;375:153–68.
11. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubsky E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–35.
12. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:240–8.
13. Pocius S, Eder JP, Fine GD, Bricl T, Lier Z, Jung H, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558–62.
14. Khuri FR, Lippman SM. Lung cancer chemoprevention. Semin Surg Oncol. 2000;18:100–5.
15. Kim C, Kim EK, Jung H, Chon HJ, Han JW, Shin KH, et al. Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer. 2016;16:434.
16. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-L1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372:311–9.

Abbreviations
ARMs: Alveolar RMS; ERMS: Embryonal RMS; FFPE: Formalin-Fixed Paraffin Embedded; FISH: Fluorescent in situ hybridization; IC: Infiltrating cells; IHC: Immunohistochemistry; NSCLC: Non-small cell lung cancer; RMS: Rhabdomyosarcoma; TC: Tumor cells
17. Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8:328rv4.

18. Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33:1430–7.

19. Chen YB, Mu CY, Huang JA. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year follow-up study. Tumori. 2012;98:751–5.

20. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104:3360–5.

21. Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007;13:1757–61.

22. Madore J, Vilain RE, Menzies AM, Kakavand H, Wilmott JS, Hyman J, et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res. 2015;28:245–53.

23. Pinto N, Park JR, Murphy E, Yearley J, McClanahan T, Annamalai L, et al. Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors. Pediatr Blood Cancer. 2017;64(11).

24. Torabi A, Amaya CN, Wians FH Jr, Bryan BA. PD-1 and PD-L1 expression in bone and soft tissue sarcomas. Pathology. 2017;49:506–13.

25. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321–30.

26. Garon EB. Cancer immunotherapy trials not immune from imprecise selection of patients. N Engl J Med. 2017;376:2483–5.